NASH Core Curriculum: Risk Factors and Prognostic Indicators

Learn about who is at risk and should be evaluated for progression to advanced fibrosis in NASH.
Manal F. Abdelmalek, MD, MPH
Format: Microsoft PowerPoint (.ppt)
File Size: 5.50 MB
Released: March 15, 2021

Acknowledgements

Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Produced in collaboration with
Supported by educational grants from
Gilead Sciences
Novo Nordisk Inc.

Related Content

Expert commentary on the use of diabetes technology according to new ADA/EASD consensus guidelines for type 1 diabetes, from Dr. Anne Peters and Clinical Care Options (CCO)

Anne Peters, MD Released: November 2, 2021

From Dr. Carol Hatch Wysham and Clinical Care Options (CCO), expert commentary on improving care for type 2 diabetes

Carol Hatch Wysham, MD Released: October 7, 2021

Expert insights on emerging NAFLD/NASH treatments from Dr. Stephen Harrison and Clinical Care Options (CCO)

Stephen Harrison, MD, FACP, FAASLD, COL (ret.) USA, MC Physicians: maximum of 0.25 AMA PRA Category 1 Credits Registered Nurses: 0.25 Nursing contact hours Pharmacists: 0.25 contact hours (0.025 CEUs) Released: September 17, 2021 Expired: September 16, 2022

Downloadable slides from CCO and Dr. Stephen Harrison highlighting take-home points about pathogenesis, risk, and treatment of NAFLD/NASH from the NASH Core Curriculum

Stephen Harrison, MD, FACP, FAASLD, COL (ret.) USA, MC Released: September 9, 2021

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue